Chronic Hepatitis C : Advances in Therapy and the Remaining Challenges
Copyright © 2023 Elsevier Inc. All rights reserved..
Hepatitis C virus (HCV) infection contributes significantly to liver cirrhosis and hepatocellular carcinoma (HCC), often requiring liver transplantation. Introducing direct-acting antiviral agents (DAAs) has radically changed HCV treatment. DAAs achieve high rates of sustained virological response (>98%). Even then, resistant-associated substitution and HCC during or after treatment have become prominent clinical concerns. Further, several clinically significant issues remain unresolved after successful HCV eradication by DAAs, including treating patients with chronic kidney disease or decompensated liver cirrhosis. Extensive and large-scale screening and treatment implementation programs are needed to make DAA therapies effective at the population level.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
The Medical clinics of North America - 107(2023), 3 vom: 01. Mai, Seite 423-433 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alqahtani, Saleh A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 04.04.2023 Date Revised 04.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mcna.2023.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355068206 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355068206 | ||
| 003 | DE-627 | ||
| 005 | 20231226063551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mcna.2023.01.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355068206 | ||
| 035 | |a (NLM)37001945 | ||
| 035 | |a (PII)S0025-7125(23)00001-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alqahtani, Saleh A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic Hepatitis C |b Advances in Therapy and the Remaining Challenges |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2023 | ||
| 500 | |a Date Revised 04.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Hepatitis C virus (HCV) infection contributes significantly to liver cirrhosis and hepatocellular carcinoma (HCC), often requiring liver transplantation. Introducing direct-acting antiviral agents (DAAs) has radically changed HCV treatment. DAAs achieve high rates of sustained virological response (>98%). Even then, resistant-associated substitution and HCC during or after treatment have become prominent clinical concerns. Further, several clinically significant issues remain unresolved after successful HCV eradication by DAAs, including treating patients with chronic kidney disease or decompensated liver cirrhosis. Extensive and large-scale screening and treatment implementation programs are needed to make DAA therapies effective at the population level | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Direct-acting antiviral agents | |
| 650 | 4 | |a HCV elimination | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a NS5A inhibitors | |
| 650 | 4 | |a Protease inhibitors | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sulkowski, Mark S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical clinics of North America |d 1945 |g 107(2023), 3 vom: 01. Mai, Seite 423-433 |w (DE-627)NLM000062588 |x 1557-9859 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2023 |g number:3 |g day:01 |g month:05 |g pages:423-433 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mcna.2023.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2023 |e 3 |b 01 |c 05 |h 423-433 | ||